Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IMVT
stocks logo

IMVT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
--
--
-0.695
-8.54%
--
--
-0.701
+9.54%
--
--
-0.785
+10.56%
Estimates Revision
Stock Price
Go Up
up Image
+33.66%
In Past 3 Month
Wall Street analysts forecast IMVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMVT is 39.63 USD with a low forecast of 16.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast IMVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMVT is 39.63 USD with a low forecast of 16.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 22.910
sliders
Low
16.00
Averages
39.63
High
54.00
Current: 22.910
sliders
Low
16.00
Averages
39.63
High
54.00
Truist
Hold
initiated
$16
2025-10-14
Reason
Truist
Price Target
$16
2025-10-14
initiated
Hold
Reason
Truist initiated coverage of Immunovant with a Hold rating and $16 price target. IMVT1402 appears to drive deeper IgG reductions than other FcRn inhibitors, but the firm thinks 1402 is too far behind in certain indications to gain meaningful traction in the market, the analyst tells investors. While aligned with the strategy of pursuing indications where 1402 would be first in class, the firm also notes that "meaningful de-risking" for these is not expected until 2027.
JPMorgan
Brian Cheng
Overweight
downgrade
$37 -> $33
2025-09-30
Reason
JPMorgan
Brian Cheng
Price Target
$37 -> $33
2025-09-30
downgrade
Overweight
Reason
JPMorgan analyst Brian Cheng lowered the firm's price target on Immunovant to $33 from $37 and keeps an Overweight rating on the shares. The firm updated the company's model.
JPMorgan
Overweight -> Overweight
downgrade
$40 -> $37
2025-08-12
Reason
JPMorgan
Price Target
$40 -> $37
2025-08-12
downgrade
Overweight -> Overweight
Reason
JPMorgan lowered the firm's price target on Immunovant to $37 from $40 and keeps an Overweight rating on the shares. The firm updated the company's model post earnings.
BofA
Jason Gerberry
Buy
downgrade
$33 -> $30
2025-08-12
Reason
BofA
Jason Gerberry
Price Target
$33 -> $30
2025-08-12
downgrade
Buy
Reason
BofA analyst Jason Gerberry lowered the firm's price target on Immunovant to $30 from $33 and keeps a Buy rating on the shares. The firm updated its model for fiscal Q1 financials, calling the quarterly update "mainly a reiteration of timelines for key R&D programs." Following the update, the firm pushed back the MG and CIDP launches to 2027-plus to reflect 1402 trial timelines, the analyst noted.
Citi
Samantha Semenkow
Buy
downgrade
$58 -> $57
2025-08-11
Reason
Citi
Samantha Semenkow
Price Target
$58 -> $57
2025-08-11
downgrade
Buy
Reason
Citi analyst Samantha Semenkow lowered the firm's price target on Immunovant to $57 from $58 and keeps a Buy rating on the shares. The firm, which continues to believe IMVT-1402 has "blockbuster potential" across multiple indications, updated its model to account for fiscal Q1 actuals. The firm's lower target is driven by higher expected operating expenses related to IMVT-1402 clinical development, the analyst noted.
UBS
Ashwani Verma
Neutral
maintain
$17 -> $18
2025-07-28
Reason
UBS
Ashwani Verma
Price Target
$17 -> $18
2025-07-28
maintain
Neutral
Reason
UBS analyst Ashwani Verma raised the firm's price target on Immunovant to $18 from $17 and keeps a Neutral rating on the shares. UBS remains cautious on the Immunovant story due to limited/no catalyst until 2027, as well as a financing overhang, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Immunovant Inc (IMVT.O) is -7.63, compared to its 5-year average forward P/E of -9.99. For a more detailed relative valuation and DCF analysis to assess Immunovant Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.99
Current PE
-7.63
Overvalued PE
-3.20
Undervalued PE
-16.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-8.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.16
Undervalued EV/EBITDA
-14.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.41
Current PS
0.00
Overvalued PS
58.30
Undervalued PS
-39.49
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 190.32% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 133.13% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 190.32% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

IMVT News & Events

Events Timeline

(ET)
2025-11-10
07:17:50
Immunovant Announces Q2 EPS of 73 Cents, Matching Consensus Estimates
select
2025-10-30 (ET)
2025-10-30
09:46:03
Betaville alert brings attention to Immunovant speculation
select
2025-09-03 (ET)
2025-09-03
13:00:44
Immunovant Reports 80% Patient Response Rate in Graves' Disease Study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-10Benzinga
Major Stocks Including Monday.Com, Metsera, and Profrac Holding Decline in Pre-Market Trading on Monday

  • U.S. Stock Futures: U.S. stock futures rose this morning, with Nasdaq futures increasing by approximately 1.5% on Monday.

  • Monday.Com Earnings: Shares of Monday.Com Ltd fell 2.6% in pre-market trading ahead of its quarterly earnings report, with analysts expecting earnings of 88 cents per share and revenue of $312.26 million.

  • Other Stocks Declining: Several stocks experienced declines in pre-market trading, including Metsera Inc, which dropped 15% after Pfizer's $10 billion acquisition deal, and Ionis Pharmaceuticals, which fell 11.5% following disappointing study results.

  • Market Overview: Other notable declines included Oscar Health Inc down 5.4%, Centene Corp down 4.8%, and Profrac Holding Corp down 2.8%, reflecting a generally negative trend among various stocks.

[object Object]
Preview
9.5
10-30Benzinga
Cardinal Health Reports Positive Q1 Results, Alongside Guardant Health, Glaukos, C.H. Robinson, and Other Major Stocks Rising on Thursday

  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones index gaining approximately 200 points on Thursday.

  • Cardinal Health's Strong Earnings: Cardinal Health, Inc. saw a significant share price increase of 17.5% after reporting better-than-expected first-quarter earnings of $2.55 per share and raising its FY25 adjusted EPS guidance.

  • Other Notable Stock Gains: Several companies, including Guardant Health, Emergent BioSolutions, and Glaukos Corporation, experienced substantial stock price increases, with gains ranging from 20% to 29.3% following positive quarterly results and raised sales guidance.

  • General Market Trends: Other companies like C.H. Robinson, Viavi Solutions, and Bausch Health also reported better-than-expected financial results, contributing to a generally positive sentiment in the market.

[object Object]
Preview
8.5
10-30SeekingAlpha
Immunovant Rises on Acquisition Rumors

  • Takeover Speculation: Immunovant's stock rose 14% due to speculation of a potential takeover, with traders referencing a Betaville "uncooked" alert.

  • Interested Buyer: Roivant, Immunovant's largest shareholder, is reportedly one of the companies interested in acquiring Immunovant.

  • Market Capitalization: Immunovant currently has a market cap of $3.8 billion.

  • Upcoming Earnings Report: The company is scheduled to report its Q3 results on November 10.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Immunovant Inc (IMVT) stock price today?

The current price of IMVT is 22.91 USD — it has increased 0.88 % in the last trading day.

arrow icon

What is Immunovant Inc (IMVT)'s business?

Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).

arrow icon

What is the price predicton of IMVT Stock?

Wall Street analysts forecast IMVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMVT is 39.63 USD with a low forecast of 16.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Immunovant Inc (IMVT)'s revenue for the last quarter?

Immunovant Inc revenue for the last quarter amounts to -131.76M USD, increased 13.84 % YoY.

arrow icon

What is Immunovant Inc (IMVT)'s earnings per share (EPS) for the last quarter?

Immunovant Inc. EPS for the last quarter amounts to -102515000.00 USD, increased 15.39 % YoY.

arrow icon

What changes have occurred in the market's expectations for Immunovant Inc (IMVT)'s fundamentals?

The market is revising No Change the revenue expectations for IMVT for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 33.66%.
arrow icon

How many employees does Immunovant Inc (IMVT). have?

Immunovant Inc (IMVT) has 362 emplpoyees as of December 05 2025.

arrow icon

What is Immunovant Inc (IMVT) market cap?

Today IMVT has the market capitalization of 4.02B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free